Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
(NASDAQ: GMAB) Delayed: 25.94 +0.33 (1.29%)
Previous Close $25.61    52 Week High $ 
Open $25.92    52 Week Low $ 
Day High $26.19    P/E N/A 
Day Low $25.85    EPS $ 
Volume 1,261,307